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Population-based case-control design has become one of the most popular approaches for conducting genome-wide
association scans for rare diseases like cancer. In this article, we propose a novel method for improving the power of the
widely used single-single-nucleotide polymorphism (SNP) two-degrees-of-freedom (2 d.f.) association test for case-control
studies by exploiting the common assumption of Hardy-Weinberg Equilibrium (HWE) for the underlying population. A key
feature of the method is that it can relax the assumed model constraints via a completely data-adaptive shrinkage estimation
approach so that the number of false-positive results due to the departure of HWE is controlled. The method is
computationally simple and is easily scalable to association tests involving hundreds of thousands or millions of genetic
markers. Simulation studies as well as an application involving data from a real genome-wide association study illustrate that
the proposed method is very robust for large-scale association studies and can improve the power for detecting susceptibility
SNPs with recessive effects, when compared to existing methods. Implications of the general estimation strategy beyond the
simple 2 d.f. association test are discussed. Genet. Epidemiol. 33:740–750, 2009. Published 2009 Wiley-Liss, Inc.y
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INTRODUCTION
The identification of large numbers of single-nucleotide
polymorphisms (SNPs) across the human genome and the
development of technologies for massive multiplex geno-
typing have now made genome-wide association studies
(GWAS) involving hundreds of thousands of markers
feasible [Hirschhorn and Daly, 2005; Thomas et al., 2005;
Wang et al., 2005]. A number of successful studies have now
been able to identify novel susceptibility loci for complex
diseases like cancer, heart disease, and diabetes [McPherson
et al., 2007; Yeager et al., 2007; Ridderstrale and Nilsson,
2008]. In GWAS, the evaluation of the association between a
disease trait and an individual SNP often constitutes the
initial analytic step. The lack of statistical significance in this
first step may lead to the exclusion of an SNP from further
scrutiny. Thus, to reduce the chance of false negatives, it is
important to use powerful methods for preliminary screen-
ing of associations.
Population-based case-control studies are now being
increasingly used for conducting genome-wide association
scans. A widely used method for testing single-SNP
associations in case-control studies is the Cochran-Armi-
tage one-degree-of-freedom trend test [Armitage, 1955;
Sasieni, 1997; Slager and Schaid, 2001; Freidlin et al., 2002],
which is known to be optimal when the mode of effect for
an SNP is multiplicative. An alternative method, which is
known to have robust power under alternative modes of
effect, is the two-degrees-of-freedom (2 d.f.) w2-test for
independence between case-control and genotype status.
The power of the standard 2 d.f. test, however, can be low
for detection of SNPs with recessive effects, often because
of the lack of sufficient sample size for homozygous
variants among the cases and controls. To resolve this
sparse data problem, we recently proposed the use of
the assumption of Hardy-Weinberg Equilibrium (HWE)
for estimation of the genotype frequencies among the
controls, then comparing the resulting distribution with
the empirical genotype distribution of the cases to obtain
a novel 2 d.f. test of association [Chen and Chatterjee,
2007]. We showed that the proposed methodology can
increase the power of 2 d.f. tests in a major way under
non-multiplicative genetic effects, with the gain being
particularly dramatic under the recessive model. A
number of other reports had also previously pointed out
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that ‘‘retrospective’’ methods for analysis of case-control
studies can exploit assumptions of HWE or a related
population genetics model to gain major power for
both genotype- and haplotype-based tests of association
[Epstein and Satten, 2003; Satten and Epstein, 2004;
Thompson et al., 2004].
A major limitation of all HWE-based tests of genetic
association is that they can lead to serious inflation of type-
I error when the underlying assumptions of HWE or other
genetic models are violated. In Chen and Chatterjee [2007],
we characterized the bias of the 2 d.f. test analytically and
showed that even the modest departure of HWE can lead
to an unacceptably high increase in the type-I error of the
procedures. The main objective of this article is to develop
a 2 d.f. test that can gain power by exploiting the model
assumptions of HWE for the underlying population and
yet be resistant to bias when the model assumptions are
violated. The method involves estimation of genotype-
specific disease odds ratio parameters by data-adaptive
‘‘shrinkage’’ of a ‘‘model-free’’ estimator that does not
require HWE assumption toward a ‘‘model-based’’ esti-
mator that directly exploits the HWE constraints. The
amount of ‘‘shrinkage’’ is sample-size-adaptive and data-
adaptive so that in large samples the method has no bias
irrespective of whether the assumptions of HWE hold and
yet the method can gain efficiency by shrinking the
analysis toward HWE, but only to the extent that the data
validate the assumptions. The closed-form expression of
the estimator itself and the availability of a simple variance
estimator facilitate rapid computation of a corresponding
Wald-type 2 d.f. test for GWAS involving hundreds of
thousands of SNPs.
We evaluate the performance of the proposed method
compared with a number of alternative tests using both
simulated and real data. In particular, we use data from
the Cancer Genetics Markers of Susceptibility (CGEMS)
study to evaluate the ability of the proposed shrinkage
estimation procedure to protect against inflated type-I
errors due to the departure of HWE that may occur on a
genome-wide scale. The study reveals potential problems
associated with the application of the so-called ‘‘retro-
spective’’ methods on a genome-wide scale, even though
the underlying assumption of HWE overall may be a good
assumption for the genome. These studies together
suggest that the proposed novel shrinkage estimation
procedure is a promising method for testing genetic
association in case-control studies. The method can gain
major power over standard case-control analysis by
exploiting the possible constraint of HWE for the under-
lying population and yet can adapt itself to protect against
inflation of type-I error when the HWE constraints are
violated. We also discuss the potential implications of
these findings beyond the context of the simple 2 d.f. test
considered in this article.
METHODS
The genotype information for an individual SNP in a
case-control study can be represented by the 2 3
contingency table presented in Table I. Here D is the
indicator of case (D 5 1) or control (D 5 0) status and G is
the number of minor alleles carried by an individual
(G 5 0, 1, 2). Let Pdg ¼ prðG ¼ gjD ¼ dÞ, d 5 0 and 1, denote
the population genotype frequencies for the controls and
the cases, respectively. The likelihood L for case-control
data is given by the product of two sets of multinomial









n1g and n0g denote numbers of cases and controls with
genotype g, respectively. In addition, define ndþ ¼P2
g¼0 ndg for d 5 0 and 1, i.e., n11 for the number of cases
and n01 for the number of controls.
We consider re-parameterizing the likelihood in terms of
alternative parameters of interest. Following Lindley
[1988], we define
y ¼ 0:5 log
4p00p02
p201




Note that y and o characterize the genotype frequencies
of the controls according to the formulas p00 ¼
e2o=ð1þ e2o þ 2eoyÞ, p01 ¼ 2eoy=ð1þ e2o þ 2eoyÞ, and
p02 ¼ 1=ð1þ e2o þ 2eoyÞ. The Hardy-Weinberg Disequili-
brium (HWD) coefficient y is a measure of the departure
from HWE among controls, with y5 0, y40, and yo0
corresponding to HWE, excess homozygosity, and excess
heterozygosity, respectively. We note that the HWE
assumption is reasonable for the underlying population,
which will include both diseased and disease-free
subjects. However, for rare diseases like certain cancers,
the assumption of HWE is reasonable in the control
population, as they approximately represent the under-
lying whole population. Further, let w ¼ ðc0;c1;c2Þ ¼
ð1;P11P00=P01P10;P12P00=P02P10Þ be the disease odds ratio
parameter vector associated with the genotypes G 5 1 and
2 relative to the baseline genotype G 5 0. Let bT ¼
ðlog P11P00=P01P10; log P12P00=P02P10Þ ¼ ðlogc1; logc2Þ.
Given y and o and hence the genotype frequency for the
controls, we can characterize the genotype frequencies for




for g ¼ 0; 1; 2: ð2Þ
Thus, the likelihood for case-control data, L 5 L(b, o, y),
is a function of w, o, and y.
Let b̂ðyÞ denote the maximum-likelihood (ML) estimate
of b for a fixed value of y. When y5 0, i.e., when HWE
holds among the controls, the ML estimate of b, denoted
by b̂ðy ¼ 0Þ, which we have shown previously [Chen and
Chatterjee, 2007], can be expressed in closed form as










TABLE I. SNP genotype frequencies in diseased (D 5 1)
and disease-free (D 5 0) subjects in the population
D 5 0 D 5 1 Total
G 5 AA P00 P10 P10
G 5 Aa P01 P11 P11
G 5 aa P02 P12 P12
Total 1 1
SNP, single-nucleotide polymorphism.
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where nE00 ¼ n0þð1 f̂Þ
2, nE01 ¼ n0þ2f̂ð1 f̂Þ, and n
E
02 ¼ n0þ f̂
2
denote the expected genotype counts for the controls
computed assuming HWE, with the estimated allele
frequency f̂ ¼ ðn01 þ 2n02Þ=2n0þ. If y is left completely
unconstrained, then the ML estimate of b is given by the
standard case-control estimator









The unconstrained ML estimator can also be expressed
as b̂ ¼ b̂ðŷÞ, where ŷ ¼ 0:5 logf4n00n02=n201g denotes the ML
estimator of y.
We propose to combine b̂ðy ¼ 0Þ and b̂ðŷÞ, the con-
strained and unconstrained estimators of b, using an
empirical-Bayes-type shrinkage estimation approach that
we developed earlier for combining alternative estimates
of the gene-environment interaction parameter obtained
with or without the assumption of gene-environment
independence in the underlying population [Mukherjee
and Chatterjee, 2008]. In particular, following a very
general formulation of the problem we described
in that article, we propose to use the composite




þ bVb̂ðbVb̂ þ D̂TŷŷTD̂Þ1b̂0
¼b̂ bVb̂ðbVb̂ þ ŷ2 D̂TD̂Þ1ðb̂ b̂0Þ; ð5Þ
where bVb̂ denotes the estimated asymptotic variance-
covariance matrix of b̂ as in Breslow and Day [1984] and
D̂ ¼ qb̂ðyÞ=qyjy¼0. We refer the reader to Mukherjee and
Chatterjee [2008] for the detailed rationale for the
estimator. Intuitively, we note that b̂EB1 is an weighted
average of the constrained and unconstrained estimators.
As the sample size increases, and hence bVb̂ decreases, the
composite estimator puts more weight on the robust
unconstrained estimator. The weight also depends on ŷ,
the data-driven estimate of the HWD coefficient. If the
absolute value of ŷ increases, i.e., if the data suggest
departure of HWE, then less weight is given to the
constrained estimator. The influence of y on the weight
depends on D̂, which determines the rate of change of b̂ðyÞ
as a function of y at the point y5 0. In the Appendix, we
derive a closed-form expression for D̂. In formula (5), the
EB estimator for b 5 (b1, b2) is presented where b is treated
as a whole vector. Alternatively, one could derive an EB
estimator for each of the two components of b separately.
In a vectorized form, we can write the alternative EB
estimator (referred to as the component-wise shrinkage
estimator, EB2) as
b̂EB2 ¼b̂ diag½bVb̂½diagðbVb̂ þ ŷ2 D̂TD̂Þ1ðb̂ b̂0Þ
¼b̂Mðb̂ b̂0Þ; ð6Þ
where diag(A) is the matrix that takes the diagonal of
matrix A but sets all the off-diagonal elements to zero and
M ¼ diagðbVb̂Þ½diagðbVb̂ þ ŷ2D̂TD̂Þ1. In the current as well
as other applications [see, e.g., Chen et al., 2009], we
have found that the component-wise method generally
produces more shrinkage compared to its multivariate
counterpart. This observation is purely based on extensive
empirical studies under several simulation settings.
Theoretical justification of the performance advantage of
EB2 over EB1 in mean-squared error (MSE) and power are
still unknown. In the current HWE context with only two
parameters, EB2 and EB1 are noted to have very similar
MSE, but EB2 has better power properties across all
scenarios. With increase in the dimension of the parameter
space, as in the haplotype-based estimation context of
Chen et al. [2009], the efficiency advantage of EB2 over
EB1 becomes more pronounced. Simulation studies
indicate that for a large number of parameters, the off-
diagonal elements of ðbVb̂Þ½ðbVb̂ þ ŷ2D̂TD̂Þ1 are quite vari-
able across the samples, which possibly offset the
advantages of a full multivariate vector-wise shrinkage.
The issue of relative efficiency of EB2 over EB1 merits
further theoretical exploration.
In the Appendix, we use the delta method to obtain
an estimate of the variance-covariance matrix (EB) for
the two EB estimators of b 5 (b1, b2). For each of the
methods, a 2 d.f. Wald test can be constructed as




EBib̂EBi, for i 5 1, 2.
We perform simulation studies to compare the type-I
error and power for four alternative tests of association: (1)
the standard unconstrained 2 d.f. test; (2) the 2 d.f. test
assuming HWE in the controls; (3) a two-step method that
first tests the HWE constraint (i.e., null hypothesis y5 0)
among the controls at a designated significance level, then
uses a constrained test if not rejected, or uses a uncon-
strained test if rejected; and (4) Wald tests based on the
proposed EB estimation procedures. In these simulation
studies, we assume that the disease susceptibility allele is
the less frequent or minor allele. Given the minor allele
frequency (MAF) f and HWD coefficient y, we calculate the
genotype frequencies for the controls, p0g, according to
formula (1). Further, given the odds ratio parameters c0 5 1
(reference group), c1, and c2, we obtain the genotype
frequencies for the cases (i.e., p1g) using formula (2). The
genotypes for the cases and the controls are then generated
from the respective multinomial distributions.
RESULTS
SIMULATION STUDIES
In the first set of simulations, we examine the type-I
errors of various tests under the null hypothesis of no
disease-genotype association. We simulate data in the
settings that involve two sample sizes (i.e., n0 5 n1 5 500
and n0 5 n1 5 2,000) and multiple combinations of coeffi-
cients y (i.e., y5 0, 0.05 log(1.2), 0.5 log(1.6), and
0.5 log(2.0), referred to as HWE, small, modest, and large
deviation from HWE, respectively) and MAFs f. We choose
the significance levels a to be 0.05 for the sample size of
500 and 1.0e5 for the sample size of 2,000. We observe
from Table II that when HWE holds, all of the different
procedures, except the two-step method, maintain the
desired type-I error level very well. The inflation of the
type-I error in the two-step method in this setting is
probably due to the fact that the procedure ignores the
variability associated with uncertainty in the underlying
model selection procedure at the first step. When HWE is
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violated, we observe that the type-I error of the con-
strained test rapidly increases with y and becomes
unacceptably high even under modest deviation from
HWE. The two-step method, although it reduces the
problem of type-I error inflation to a large extent, can still
produce a large inflation of the type-I error. The EB
procedures provide much better control of type-I error,
compared with both the constrained and the two-step
method. In particular, it is encouraging to note that when
the departure of HWE is small, say jyj  0:5 logð1:2Þ, a
range where the large majority of HWE departures are
likely to appear in practice (see, e.g., Fig. 3 in the CGEMS
application), the type-I errors of the EB procedures are
generally very close to the nominal level. As y further
increases, the type-I errors of the EB procedures initially
increase and then eventually again decrease.
In the next set of simulations, we assume HWE in the
control population and explore the power of various test
procedures under different combinations of MAF and
odds ratio parameters. Figure 1 displays the power curves
estimated from 10,000 simulated data sets of 500 cases and
500 controls. It is clear that in this setting the constrained
test can gain major power over the unconstrained test,
especially when the true effect of the genotype is recessive.
The EB1 test procedure, although it gives up some
efficiency compared with the constrained test, retains a
major power advantage over the unconstrained test for
detecting recessive genetic effects. The power of EB1 was
slightly lower than that of EB2 (not shown in Fig. 1). The
power of the two-stage test lies between the unconstrained
and constrained tests, as expected.
In Table III, we show the power for various tests of
association under the recessive model and different
combinations of the MAF f and the HWE coefficient y.
We observe that when there is small departure from HWE,
a scenario that is likely to be common in practice, the EB
procedures can maintain desired type-I error levels fairly
well (as seen in Table II) and yet can gain substantial
power over the unconstrained test. Similar comparisons
for the dominant model are shown in Table IV. Here we
observe that under small departures from HWE, the EB
procedures generally perform similarly to the uncon-
strained test. Under large departures from HWE, however,
the EB procedures can sometimes have a substantial loss of
power compared with the unconstrained test. Since some
of the tests we consider do not strictly maintain type-I
error under the departure of HWE, we also provide MSE
for the parameter estimates as an alternative way of
comparing the performance of the different estimators.
The results are similar to those presented in Mukherjee
and Chatterjee [2008]. Under HWE, the EB methods
produce MSE comparable to the constrained estimator,
which has the smallest MSE. Under departures from HWE,
the EB methods produce the smallest or close to the
smallest MSE among all methods we considered (as shown
in Tables III and IV).
TABLE II. The type-I error for alternative tests under the null hypothesis of no disease-genotype association (i.e.,
wAa 5 waa 5 1)
HWD coeff. (y) MAF Unconstrained Constrained Two-step EB1 EB2
500 cases and 500 controls, a5 0.05, 10,000 simulations
y5 0 0.1 0.03 0.04 0.04 0.03 0.03
0.2 0.05 0.05 0.06 0.04 0.04
0.3 0.05 0.05 0.06 0.04 0.04
y5 0.5 log(1.2) 0.1 0.03 0.07 0.07 0.04 0.04
0.2 0.05 0.09 0.09 0.05 0.06
0.3 0.05 0.11 0.11 0.06 0.07
y5 0.5 log(1.6) 0.1 0.03 0.15 0.13 0.06 0.07
0.2 0.05 0.31 0.22 0.09 0.11
0.3 0.05 0.50 0.23 0.08 0.12
y5 0.5 log(2.0) 0.1 0.03 0.24 0.18 0.08 0.09
0.2 0.04 0.57 0.22 0.07 0.11
0.3 0.05 0.82 0.13 0.06 0.10
2,000 cases and 2,000 controls, a5 1.0e5, 1 million simulations
y5 0 0.1 3.0e6 8.0e6 1.0e5 3.0e6 3.0e6
0.2 1.0e5 1.4e5 1.8e5 1.1e5 1.3e5
0.3 1.6e5 1.1e5 2.1e5 8.0e6 8.0e6
y5 0.5 log(1.2) 0.1 4.0e6 2.6e4 2.3e4 5.5e5 6.5e5
0.2 1.7e5 8.0e4 6.1e4 1.3e4 1.9e4
0.3 1.1e5 2.1e3 1.3e3 2.3e4 3.6e4
y5 0.5 log(1.6) 0.1 1.0e6 9.0e3 4.9e3 6.8e4 8.1e4
0.2 5.0e6 0.11 1.1e2 4.7e4 9.7e4
0.3 8.0e6 0.39 3.5e3 7.9e5 3.7e4
y5 0.5 log(2.0) 0.1 3.0e6 5.9e2 1.5e2 1.4e3 1.7e3
0.2 5.0e6 0.57 2.3e3 5.1e5 1.8e4
0.3 1.1e5 0.95 2.0e5 1.0e5 3.1e5
Results are obtained based on simulating case-control data sets with either 500 cases and 500 controls (upper panel) or 2,000 cases and 2,000
controls (lower panel). Desired significance level of the tests are assumed to be a5 0.05 and 105 for studies with 500 and 2,000 cases,
respectively. Empirical significance levels of the tests are obtained by 10,000 and 1 million simulations, respectively. HWD, Hardy-Weinberg
Disequilibrium; MAF, minor allele frequency.
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THE CANCER GENETICS MARKERS OF SUSCEP-
TIBILITY (CGEMS) STUDY
We evaluate the performance of alternative 2 d.f. tests of
association using data from the CGEMS study, an NCI
enterprise initiative to conduct multi-stage whole-genome
association studies to identify genes giving rise to
increased risks of prostate and breast cancers. In this
article, we will focus on data from the initial scan for the
prostate cancer study, involving genotype data on about
550,000 SNPs from 1,172 cases and 1,157 controls. An
initial report from the study describing the increased risk
of prostate cancer associated with the 8q24 region has been
published [Yeager et al., 2007]. Sequential replication
studies are now ongoing for about 5% of the SNPs that
are considered to be promising based on the data from the
initial scan. The details of the CGEMS study design and
the results from the initial scan can be found at the website
https://caintegrator.nci.nih.gov/cgems/.
Figure 2 shows the Q-Q plots associated with 449,698
SNPs from 22 non-sex chromosomes with MAFs larger than
0.05 for the four different tests of association: (i) uncon-
strained; (ii) constrained; (iii) two-stage; and (iv) EB2. Each
plot in the figure displays the empirical percentile of the P-
values associated with one of the four 2 d.f. tests against the
percentiles of the expected null distribution. For a well-
designed study and a robust analytic method, Q-Q plots for
GWAS are expected to follow the diagonal lines closely,
given that at most a handful of the SNPs are likely to be
truly associated with the disease. Thus, large-scale departure
of the Q-Q plot from the expected diagonal is often
considered to be indicative of bias in the underlying study
design or/and analytic method.
In Figure 2, we observe that the Q-Q plot for the
unconstrained test closely follows the diagonal line except
at the extreme tail of the distributions, where Po104. This
plot suggests that the CGEMS study does not suffer from
any large-scale systematic bias such as those due to
population stratification or differential genotyping error.
Moreover, the standard 2 d.f. test of association is a robust
method for analysis of data from this study. In contrast, we
observe that the Q-Q plot for the constrained test departs




































































































































Fig. 1. Power comparison for alternative case-control tests of association: (i) a standard 2 d.f. test (unconstrained), (ii) a 2 d.f. test
assuming HWE in controls (constrained), (iii) a two-step test that selects between the constrained and unconstrained tests based on a
test of HWE among the controls, and (iv) the proposed EB tests. Data are simulated for a case-control study of 500 cases and 500 controls,
assuming that HWE holds for the underlying population. The effect of the SNP on the risk of the disease is assumed to follow either a
dominant (upper panel) or a recessive pattern (lower panel). All of the tests are performed at a significance level of a 5 0.05. HWE,
Hardy-Weinberg Equilibrium; 2 d.f., two degrees of freedom; SNP, single-nucleotide polymorphism.
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dramatically from the diagonal line in the range of
Po102. For example, the constrained test finds 1,716
SNPs to have P-values less than 103, while under the
null hypothesis of no association, only 450 (i.e.,
449,698 103C450) such SNPs would be expected in
the study. This indicates a major inflation of the type-I
error for the constrained test due to departure of the HWE
assumption. The Q-Q plot corresponding to the two-step
procedure suggests that although the type-I error inflation
is substantially reduced compared with the constrained
test, it still remains significantly higher than desired. The
two-step method, for example, finds 122 SNPs to have
P-values less than 104, while under the null hypothesis of
no association, only 45 (i.e., 449,698 104C45) such SNPs
would be expected. The Q-Q plot for the EB2 procedure
strikingly resembles that of the robust unconstrained test.
The plot closely follows the diagonal line except at the
extreme tail of the distribution. The pattern provides
empirical evidence that EB-type procedures perform very
well in controlling the type-I error rates for the related tests
of association under realistic departures from HWE that
may arise in GWAS. We refrain from presenting the Q-Q
plot for the EB1 procedure in this example as it appears to
be very similar to EB2, and EB2 does have a slight edge
over EB1 in terms of power for detecting disease-SNP
association.
In Figure 3, we show the histogram of the estimated
HWD coefficient y for the 449,698 SNPs we studied. It is
clear that, overall, HWE is a good assumption for the
genome, with 69.6 and 96.7% of the estimated coefficients
falling between the 70.5 log(1.2) and 70.5 log(1.6) limits,
respectively. Nevertheless, a test based on the assumption
of HWE can lead to a major inflation of type-I error for
large-scale studies.
The CGEMS group has recently reported results from a
replication study involving 3,941 cases and 3,964 controls
[Thomas et al., 2008]. Based on a ‘‘joint analysis’’ of the
initial scan and replication study, the report has listed 17
SNPs that have met genome-wide significance for their
association with prostate cancer. Given that associations of
these SNPs with prostate cancer are now considered to be
‘‘replicated,’’ we can use these SNPs to evaluate the power
of alternative methods for the analysis of the initial
CGEMS scan. From the results shown in Table V, we
observe that for 12 out of the 17 SNPs (rows 1–12 of
Table V), both EB-based procedures produce smaller
P-values than the standard 2 d.f. test, while for 2 other
SNPs (rows 13 and 14 of Table V), one of the EB-based
procedures produces smaller P-values. The decrease in
P-values, however, is quite modest in general. These
results are intuitive, given that none of the SNPs shows
a genotype odds ratio pattern that resembles a recessive
model, under which we would have expected to see
a larger gain in power by exploiting the HWE assumption.
DISCUSSION
In this article, we propose a powerful test for genetic
association in case-control studies by exploiting the
common assumption of HWE for the underlying popula-
tion. Unlike previous methods that have also aimed to gain
TABLE III. The power for different tests and mean-squared error corresponding to the estimate of log(waa) (in parentheses)
Sample size HWD coeff. (y) MAF Unconstrained Constrained Two-step EB1 EB2
N 5 500 y5 0 0.1 0.120 (0.383) 0.379 (0.171) 0.371 (0.205) 0.224 (0.232) 0.233 (0.229)
0.2 0.556 (0.087) 0.834 (0.056) 0.821 (0.065) 0.707 (0.066) 0.756 (0.063)
0.3 0.883 (0.043) 0.980 (0.035) 0.973 (0.037) 0.940 (0.037) 0.967 (0.036)
y5 0.5 log(1.2) 0.1 0.118 (0.378) 0.517 (0.180) 0.484 (0.211) 0.283 (0.235) 0.306 (0.228)
0.2 0.575 (0.082) 0.945 (0.065) 0.874 (0.071) 0.735 (0.068) 0.809 (0.064)
0.3 0.893 (0.043) 0.999 (0.042) 0.959 (0.043) 0.930 (0.041) 0.973 (0.040)
y5 0.5 log(1.6) 0.1 0.125 (0.367) 0.721 (0.288) 0.598 (0.310) 0.331 (0.276) 0.372 (0.268)
0.2 0.595 (0.082) 0.993 (0.135) 0.754 (0.117) 0.656 (0.089) 0.776 (0.087)
0.3 0.905 (0.040) 1.000 (0.071) 0.911 (0.053) 0.897 (0.045) 0.963 (0.046)
y5 0.5 log(2.0) 0.1 0.126 (0.365) 0.822 (0.435) 0.581 (0.409) 0.322 (0.319) 0.375 (0.310)
0.2 0.605 (0.080) 0.999 (0.228) 0.656 (0.126) 0.619 (0.097) 0.755 (0.096)
0.3 0.916 (0.038) 1.000 (0.111) 0.916 (0.045) 0.884 (0.043) 0.964 (0.045)
N 5 2,000 y5 0 0.1 0.003 (0.082) 0.228 (0.039) 0.218 (0.051) 0.086 (0.054) 0.098 (0.052)
0.2 0.520 (0.021) 0.965 (0.014) 0.943 (0.016) 0.782 (0.016) 0.859 (0.015)
0.3 0.986 (0.011) 1.000 (0.009) 0.997 (0.009) 0.994 (0.010) 0.999 (0.009)
y5 0.5 log(1.2) 0.1 0.003 (0.081) 0.500 (0.057) 0.438 (0.068) 0.166 (0.062) 0.190 (0.060)
0.2 0.548 (0.020) 0.999 (0.026) 0.808 (0.025) 0.654 (0.020) 0.786 (0.020)
0.3 0.989 (0.010) 1.000 (0.014) 0.990 (0.013) 0.986 (0.011) 0.997 (0.011)
y5 0.5 log(1.6) 0.1 0.003 (0.079) 0.862 (0.174) 0.462 (0.128) 0.123 (0.087) 0.149 (0.087)
0.2 0.585 (0.020) 1.000 (0.093) 0.592 (0.026) 0.505 (0.023) 0.675 (0.024)
0.3 0.993 (0.010) 1.000 (0.044) 0.993 (0.010) 0.982 (0.011) 0.997 (0.012)
y5 0.5 log(2.0) 0.1 0.004 (0.078) 0.968 (0.336) 0.248 (0.134) 0.052 (0.097) 0.071 (0.096)
0.2 0.613 (0.019) 1.000 (0.184) 0.613 (0.019) 0.501 (0.022) 0.682 (0.022)
0.3 0.995 (0.010) 1.000 (0.085) 0.995 (0.010) 0.978 (0.011) 0.997 (0.010)
The disease-genotype odds ratios are assumed to follow a ‘‘recessive’’ pattern with cAa 5 1, caa 5 1.4
2. Results are based on 10,000
simulated case-control data sets, each with 500 cases and 500 controls (upper panel), and on 1,000,000 simulated case-control data sets, each
with 2,000 cases and 2,000 controls (lower panel). All tests are performed at a significance level of a5 0.05 for the study with 500 cases and
a5 105 for the study with 2,000 cases. HWD, Hardy-Weinberg Disequilibrium; MAF, minor allele frequency.
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efficiency for case-control association testing by exploiting
HWE for the underlying population, the proposed EB
procedure can data-adaptively relax the underlying con-
straints and thus can reduce the chance of false-positive
results when the HWE assumption is violated. Simulation
studies as well as an application involving a GWAS show
that the EB procedure can maintain appropriate control
over the type-I error rate for large-scale studies that would
have natural deviations from HWE of varying degrees
across different loci. Further, our studies illustrate that the
EB procedure has a major power advantage over standard
case-control tests for the detection of susceptibility SNPs
with effects resembling a ‘‘recessive’’ pattern. In addition,
the closed-form expression of the EB estimators and the
simple corresponding variance estimation make the
computation cost comparable to that of the unconstrained
test in the study setting of GWAS.
The pattern of power seen for different methods under
different models for genetic effects is intuitive. The
constrained test gains power over its unconstrained
counterpart by incorporating additional information from
the departure of the observed genotype distribution in the
case-control sample from the assumed HWE model for the
population. If an SNP is under HWE in the population, its
genotype distribution approximately follows HWE in the
controls, under the assumption of rare disease. Moreover,
when the effect of an SNP is multiplicative (log-additive)
per copy of an allele, it can be shown that, again assuming
rare disease, the HWE for the population implies HWE
for the cases [Sasieni, 1997]. It is expected that when the
TABLE IV. The power for different tests and sum of mean-squared errors corresponding to the point estimates of log(wAa)
and log(waa) (in parentheses)
Sample size HWD coeff. (y) MAF Unconstrained Constrained Two-step EB1 EB2
N 5 500 y5 0 0.1 0.465 (0.479) 0.498 (0.275) 0.507 (0.308) 0.477 (0.329) 0.482 (0.324)
0.2 0.637 (0.123) 0.693 (0.089) 0.697 (0.098) 0.664 (0.100) 0.677 (0.096)
0.3 0.656 (0.069) 0.741 (0.057) 0.740 (0.060) 0.700 (0.060) 0.714 (0.058)
y5 0.5 log(1.2) 0.1 0.455 (0.471) 0.460 (0.273) 0.478 (0.308) 0.446 (0.323) 0.437 (0.314)
0.2 0.621 (0.120) 0.600 (0.099) 0.622 (0.107) 0.598 (0.103) 0.593 (0.098)
0.3 0.651 (0.067) 0.602 (0.066) 0.639 (0.068) 0.610 (0.064) 0.611 (0.062)
y5 0.5 log(1.6) 0.1 0.420 (0.472) 0.447 (0.368) 0.473 (0.402) 0.389 (0.362) 0.365 (0.349)
0.2 0.621 (0.119) 0.614 (0.173) 0.658 (0.154) 0.549 (0.124) 0.530 (0.123)
0.3 0.659 (0.066) 0.629 (0.112) 0.688 (0.084) 0.565 (0.072) 0.580 (0.075)
y5 0.5 log(2.0) 0.1 0.384 (0.468) 0.482 (0.519) 0.485 (0.507) 0.351 (0.408) 0.323 (0.395)
0.2 0.600 (0.113) 0.714 (0.273) 0.667 (0.165) 0.489 (0.131) 0.478 (0.133)
0.3 0.658 (0.064) 0.789 (0.176) 0.686 (0.074) 0.516 (0.071) 0.575 (0.076)
N 5 2,000 y5 0 0.1 0.370 (0.103) 0.428 (0.059) 0.431 (0.071) 0.397 (0.073) 0.417 (0.071)
0.2 0.690 (0.029) 0.792 (0.021) 0.790 (0.024) 0.744 (0.024) 0.770 (0.023)
0.3 0.718 (0.017) 0.853 (0.014) 0.847 (0.015) 0.793 (0.015) 0.816 (0.015)
y5 0.5 log(1.2) 0.1 0.329 (0.101) 0.314 (0.076) 0.334 (0.087) 0.307 (0.079) 0.297 (0.077)
0.2 0.674 (0.029) 0.614 (0.034) 0.661 (0.034) 0.624 (0.028) 0.612 (0.028)
0.3 0.723 (0.017) 0.621 (0.022) 0.702 (0.020) 0.651 (0.017) 0.648 (0.018)
y5 0.5 log(1.6) 0.1 0.269 (0.099) 0.285 (0.191) 0.301 (0.148) 0.217 (0.106) 0.178 (0.105)
0.2 0.642 (0.028) 0.620 (0.108) 0.651 (0.034) 0.515 (0.032) 0.490 (0.034)
0.3 0.729 (0.016) 0.671 (0.069) 0.731 (0.016) 0.588 (0.017) 0.641 (0.019)
y5 0.5 log(2.0) 0.1 0.225 (0.098) 0.374 (0.354) 0.277 (0.154) 0.152 (0.117) 0.112 (0.118)
0.2 0.613 (0.027) 0.830 (0.210) 0.614 (0.028) 0.400 (0.032) 0.446 (0.032)
0.3 0.728 (0.016) 0.930 (0.134) 0.728 (0.016) 0.491 (0.018) 0.652 (0.017)
The disease-genotype odds ratios are assumed to follow a ‘‘dominant’’ pattern with cAa 5caa 5 1.4. Results are based on 10,000 simulated
case-control data sets, each with 500 cases and 500 controls (upper panel), and on 1,000,000 simulated case-control data sets, each with 2,000
cases and 2,000 controls (lower panel). All tests are performed at a significance level of a5 0.05 for the study with 500 cases and a5 105 for
the study with 2,000 cases. HWD, Hardy-Weinberg Disequilibrium; MAF, minor allele frequency.
Fig. 2. Q-Q plots for the CGEMS genome-wide association
study of prostate cancer. Each panel represents a plot for the
percentiles of the observed P-values, obtained from a specific
test of association, against those expected under the ‘‘null’’
hypothesis of no association. The solid line represents the
diagonal Y 5 X. CGEMS, Cancer Genetics Markers of Suscep-
tibility.
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non-multiplicative effect of an SNP is larger, so is the
departure for the distribution of its genotypes from HWE,
in the cases and hence in the case-enriched case-control
sample. Thus, the efficiency gains for the constrained and
the EB-type shrinkage procedures over the unconstrained
one are expected to be increasing with the magnitude of
the non-multiplicative effect of an SNP. In our simulation,
under the multiplicative model for the effect of an SNP, we
do not see any difference in efficiency among the methods
(results not shown). Under the dominant model, which
corresponds to modest departure from the multiplicative
model, we observe some gain in efficiency for the
















Fig. 3. Histogram of estimates of h, a log-odds-ratio measure of Hardy-Weinberg Disequilibrium, for the 449,698 SNPs studied in 22
non-sex chromosomes in the CGEMS study with minor allele frequencies larger than 0.05. The values h 5 0, h40, and ho0 correspond
to HWE, excess homozygosity, and excess heterozygosity, respectively. SNP, single-nucleotide polymorphism; CGEMS, Cancer Genetics
Markers of Susceptibility; HWE, Hardy-Weinberg Equilibrium.
TABLE V. The comparison of the P-values of various tests of association for specific target SNPs in the CGEMS study
Overall
SNP MAF Unconstrained Constrained Two-step EB1 EB2
rs4242382 0.100 3.60e5 2.71e5 2.71e5 3.06e5 3.17e5
rs4242384 0.099 3.42e5 2.75e5 2.75e5 2.82e5 2.82e5
rs1447295 0.102 1.78e4 1.38e4 1.38e4 1.34e4 1.44e4
rs7837688 0.097 1.29e5 5.24e6 5.24e6 5.65e6 5.67e6
rs11988857 0.117 2.30e5 2.41e5 2.41e5 1.84e5 1.89e5
rs10993994 0.365 2.64e3 1.22e3 1.22e3 2.54e3 1.57e3
rs9656816 0.088 1.20e3 5.22e4 5.22e4 8.71e4 9.80e4
rs6983267 0.489 1.04e2 7.68e3 7.68e3 7.65e3 7.60e3
rs4430796 0.489 9.99e3 3.59e3 3.59e3 3.57e3 3.54e3
rs7501939 0.421 5.37e3 4.32e4 4.32e4 1.33e3 9.07e4
rs7014346 0.350 5.50e3 4.69e3 4.69e3 4.84e3 4.76e3
rs7837328 0.394 2.48e3 2.33e3 2.33e3 2.41e3 2.38e3
rs1106207 0.428 3.46e3 3.97e4 3.46e4 5.23e3 2.32e3
rs7017300 0.131 4.83e5 6.65e5 6.65e5 4.21e5 5.21e5
rs4962416 0.263 9.89e5 6.65e5 6.65e5 1.40e4 1.09e4
rs1486567 0.231 4.26e2 5.13e2 5.13e2 5.48e2 4.91e2
rs10896449 0.490 0.024 0.094 0.094 0.064 0.071
SNP, single-nucleotide polymorphism; CGEMS, Cancer Genetics Markers of Susceptibility; MAF, minor allele frequency.
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constrained and the EB procedures. Under the recessive
model, which corresponds to large departure from the
multiplicative effect, we observe the highest gain in
efficiency for the constrained and the EB procedures.
In this article, we have focused on the 2 d.f. single-SNP
test of genetic association. The proposed shrinkage
estimation strategy, however, can be used to improve the
power of other types of genetic association tests in case-
control studies. For single-SNP association testing with
unknown modes of genetic effect, for example, a popular
alternative to the 2 d.f. test is the MAX procedure which
uses the maximum of the single-SNP Z-statistics for the
additive, dominant, and recessive models as the test
statistics for detecting association. For case-control studies,
the power of the MAX procedure can potentially be
improved by deriving the component Z-statistics by
exploiting the HWE constraints for the genotype distribu-
tion of the controls. In particular, the proposed shrinkage
estimation strategy can be used to estimate the disease-
genotype odds ratios and their standard errors under
alternative modes of genetic effect and hence to derive the
corresponding Wald statistics.
The proposed shrinkage estimation strategy can also
potentially be used to improve the power of case-control
genetic association tests involving loci with more than two
alleles. The general strategy would involve first estimating
disease-genotype odds ratios, once using the empirical
genotype frequency for the controls, once assuming HWE
constraints for the controls, then combining the two
estimators using the empirical-Bayes-type weighting strat-
egy proposed here. Further research is merited on the
development of such multi-allelic tests, especially in
the context of haplotype-based association studies, where
the additional complexity arises from the fact that
haplotype-phase information is typically missing from
the observable genotype data.
In conclusion, we believe that the proposed shrinkage
estimation strategy, considering its power, robustness,
generalizability, and computational simplicity, overall is a
promising approach for detecting genetic associations
from case-control studies.
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APPENDIX A
A.1. DERIVATION OF D̂
The likelihood function for controls, L0, which is








ð1þ ey cosh oÞn0þ
;
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where the hyperbolic cosine cosho ¼ ðeo þ eoÞ=2.
Taking the derivative of the logarithm of L0 with respect
to o, we get
q log L0
qo




where the hyperbolic sine sinho ¼ ðeo  eoÞ=2. Equating
the last equation to zero, taking the derivative on both




ðy ¼ 0Þ ¼
n00  n02
ðn00  n02Þ sinh ô n0þ cosh ô
:
The unconstrained ML estimator b̂ ¼ b̂ðy ¼ ŷÞ in (4) can
be expressed in terms of ŷ and ô as













ðy ¼ 0Þ ¼ ð1þ k; 2kÞ:
A.2. VARIANCE CALCULATION FOR THE EB1
ESTIMATOR
We note that the total numbers of cases and controls, n01
and n11, are fixed by the study design. The cell counts for
genotype AA, Aa, and aa both in cases and controls follow
a multinomial distribution and the cases are independent
of the controls. Then the variance-covariance matrix for the
cell count vector n ¼ ðn11; n12; n01; n02Þ





































We notice that the matrix ðbVb̂ þ D̂TŷŷTD̂Þ1 in (5) is of the
form ðV þ uuTÞ1. From matrix algebra, we know that
ðV þ uuTÞ1 ¼ V1  ðV1uÞðuTV1Þ=ð1þ uTV1uÞ. Then
we can simplify (5) as
















Since bVb̂ and D̂ approach zero at the rate of O(1/n), we
may ignore the variation in bVb̂ and D̂ and treat them as
constants while computing the variance-covariance matrix
of the EB1 estimator. Then the EB1 estimator can be
viewed as a fixed function of the cell count vector n. Take
the derivative of the EB1 estimator with respect to the cell
count vector n. The corresponding gradient matrix A1 is
A1 ¼ ðqb̂EB1=qn11; qb̂EB1=qn12; qb̂EB1=qn01; qb̂EB1=qn02Þ. The


























































n1þ  n11  n12
1

























n0þ  n01  n02
1









































































2ðn0þ  n01  n02Þ
:
The variance-covariance matrix of the EB1 estimator,
denoted by EB1, is given by A1BAT1, where T represents the
matrix transpose.
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A.3. VARIANCE CALCULATION FOR THE EB2
ESTIMATOR
The derivation of the variance for the EB2 esti-
mator follows that of the EB1 estimator. Note that (6)
is also a function of the cell count vector n. Take
the derivative of the EB2 estimator with respect to
the vector n. The corresponding gradient matrix









































for j ¼ 1; 2;
where qb̂=qn0j, qb̂
0
=qn0j, and qŷ=qn0j are computed in the
section ‘‘Derivation of D̂.’’
The variance-covariance matrix of the EB2 estimator,
denoted by EB2, is computed as A2BAT2 , where B is shown
in the section ‘‘Derivation of D̂.’’
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